

ASX RELEASE**VOLPARA COLLABORATES WITH LEADING GENETICS COMPANY, INVITAE CORPORATION**

Wellington, NZ, 19 July 2021: Volpara Health Technologies Limited (“Volpara,” “the Group,” or “the Company”; ASX:VHT), a global health technology software leader providing an integrated breast care platform for the delivery of personalised breast care, has entered into a collaboration agreement with Invitae Corporation (“Invitae”), a leader in medical genetics, to bring Invitae’s genetic testing services to Volpara’s customers in the United States.

Highlights:

- **Volpara’s customers in the United States will get access to Invitae’s comprehensive genetic testing services within Volpara’s software workflow**
- **Volpara plans to create a fully integrated ordering process for Invitae genetic testing services within Volpara’s suite of products**
- **As part of this collaboration agreement with Invitae, Volpara has the potential to offer increased value to mutual customers upon successful clinical implementation**

Volpara will integrate Invitae into Volpara’s software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings. At least one Volpara software product is used with over 32% of women who attend screening each year in the United States. Customers utilize Volpara’s market-leading breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalised risk.

Risk assessment is also required by insurance companies in the United States to justify reimbursement for additional testing. Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival.

Dr. Ralph Highnam, Group CEO of Volpara said “Volpara continues to be proud of its major role in driving the adoption of personalised breast screening in the United States. Our relationship with Invitae adds a prominent partner to our breast health platform and will allow us to offer increased value to our customers by ensuring that the right patients get seamless access to the right genetic testing at the right time.”

Authorisation & Additional Information

This announcement was authorised by the Group CEO Dr Ralph Highnam.

Authorisation & Additional Information

For further information, please contact:

Ralph Highnam, CEO

Volpara Health Technologies

ralph.highnam@volparahealth.com

t: +64 21 149 0541

Trevor Chappell

WE Communications

WE-AUVolpara@we-worldwide.com

t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT’s clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT’s technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020 and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com